Sk Biopharmaceutica (Korea) Today
| 326030 Stock | 100,900 5,500 5.77% |
Performance0 of 100
| Odds Of DistressLess than 37
|
Sk Biopharmaceutica is trading at 100900.00 as of the 25th of November 2024, a 5.77 percent increase since the beginning of the trading day. The stock's open price was 95400.0. Sk Biopharmaceutica has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Sk Biopharmaceuticals Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Moving together with 326030 Stock
Moving against 326030 Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
326030 Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sk Biopharmaceutica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sk Biopharmaceutica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Pres | Jeong Cho |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Sk Biopharmaceuticals Co (326030) is traded on Korea Stock Exchange in Korea and employs 10 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 5.32 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sk Biopharmaceutica's market, we take the total number of its shares issued and multiply it by Sk Biopharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sk Biopharmaceuticals operates under Healthcare sector and is part of Biotechnology industry. The entity has 78.31 M outstanding shares.
Sk Biopharmaceutica generates negative cash flow from operations
Check Sk Biopharmaceutica Probability Of Bankruptcy
Ownership AllocationSk Biopharmaceuticals secures a total of 78.31 Million outstanding shares. Sk Biopharmaceuticals owns majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.28 % of Sk Biopharmaceuticals Co outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check 326030 Ownership Details
Sk Biopharmaceuticals Risk Profiles
Although Sk Biopharmaceutica's alpha and beta are two of the key measurements used to evaluate Sk Biopharmaceutica's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.14 | |||
| Standard Deviation | 2.82 | |||
| Variance | 7.97 | |||
| Risk Adjusted Performance | 0.003 |
326030 Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sk Biopharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Sk Biopharmaceutica Corporate Management
Elected by the shareholders, the Sk Biopharmaceutica's board of directors comprises two types of representatives: Sk Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 326030. The board's role is to monitor Sk Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sk Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sk Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wanho Nam | VP HR | Profile | |
| Sungwan Hwang | VP Innovation | Profile | |
| Jooyup Chae | VP Counsel | Profile | |
| HyungRae Cho | F Exec | Profile |
Other Information on Investing in 326030 Stock
Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.